Breast Cancer Gene Panel – Comprehensive

Overview

A Breast Cancer Gene Panel is an advanced molecular genetic test used to identify inherited mutations associated with an increased risk of breast cancer and related hereditary cancers. This comprehensive panel analyzes multiple clinically significant genes involved in DNA repair, tumor suppression, and hereditary cancer syndromes.

The test helps in:

• Assessing hereditary breast cancer risk
• Guiding treatment decisions
• Supporting preventive care strategies
• Identifying cancer risks in family members
• Evaluating risk for ovarian, pancreatic, prostate, and other cancers

Clinical Indications

Recommended for individuals with:

• Personal history of breast cancer
• Early-onset breast cancer
• Triple-negative breast cancer
• Bilateral or multiple primary cancers
• Family history of breast/ovarian cancer
• Male breast cancer
• Known familial cancer mutation
• Recurrent or metastatic breast cancer
• Ashkenazi Jewish ancestry with cancer history
• Strong hereditary cancer syndrome suspicion

Genes Commonly Included

The comprehensive panel may include analysis of:

High-Risk Genes

• BRCA1
• BRCA2
• TP53
• PALB2
• PTEN
• CDH1
• STK11

Moderate-Risk Genes

• ATM
• CHEK2
• NBN
• BARD1
• RAD51C
• RAD51D
• BRIP1
• NF1

Additional Hereditary Cancer Genes

• MLH1
• MSH2
• MSH6
• PMS2
• EPCAM
• MUTYH
• FANCM
• RECQL
• XRCC2

Gene composition may vary depending on laboratory protocols.

Methodology

• Next Generation Sequencing (NGS)
• Deletion/Duplication analysis (MLPA or equivalent)
• Bioinformatics variant interpretation
• ACMG guideline-based classification

Sample Type

• Peripheral Blood (EDTA)
• Saliva/Buccal sample (where applicable)

Patient Preparation

No special preparation or fasting required.

Turnaround Time

Approximately 2–4 weeks depending on panel complexity.

Interpretation of Results

Positive

Pathogenic or likely pathogenic mutation detected.

• Indicates increased hereditary cancer risk
• May influence surveillance and treatment

Negative

No clinically significant mutation detected.

• Does not completely eliminate cancer risk

Variant of Uncertain Significance (VUS)

Genetic alteration detected with unclear clinical significance.

• Periodic re-evaluation may be recommended

Clinical Utility

• Hereditary cancer risk assessment
• Personalized cancer screening
• Targeted therapy selection
• Family cascade testing
• Preventive management planning
• Surgical decision support

Possible Management Recommendations

Depending on results and clinical history:

• Enhanced breast screening (MRI/Mammogram)
• Preventive medications
• Risk-reducing surgery
• Family genetic counseling
• Personalized oncology treatment

Limitations

• Not all cancer-causing variants may be detected
• A negative result does not exclude hereditary cancer completely
• Interpretation depends on current scientific evidence

Associated Cancers

Mutations detected may also be associated with:

• Ovarian cancer
• Pancreatic cancer
• Prostate cancer
• Colorectal cancer
• Gastric cancer
• Melanoma
• Endometrial cancer

Recommended Follow-Up

• Genetic counseling before and after testing
• Oncology consultation
• Family risk assessment
• Periodic surveillance planning

Technology Highlights

• High-depth sequencing coverage
• Comprehensive hereditary cancer analysis
• Clinically validated workflow
• Advanced variant interpretation system

Disclaimer

This test is intended for clinical and diagnostic purposes and should be interpreted by qualified healthcare professionals along with clinical findings, family history, and other laboratory investigations.